News about "Drug Development"

Bayer to Acquire Perfuse Therapeutics to Boost Ophthalmology Pipeline

Bayer to acquire Perfuse Therapeutics, strengthening its ophthalmology pipeline with a potential disease-modifying therapy for glaucoma and diabetic retinopathy.

Drug Development | 07/05/2026 | By News Bureau

Alloy Therapeutics and IPI Partners to Advance Next-Gen Antibody Discovery

Alloy Therapeutics and IPI collaborate to develop advanced VHH libraries for faster, more efficient next-generation antibody discovery.

Drug Development | 06/05/2026 | By News Bureau

AbbVie Provides US Regulatory Update on TrenibotE BLA

AbbVie gets US FDA Complete Response Letter (CRL) for TrenibotE BLA tied to manufacturing processes; no new clinical studies needed.

Drug Development | 24/04/2026 | By News Bureau

Piramal Pharma Solutions Expands ADC Capabilities with Ajinomoto Bio-Pharma Services Pact

Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to accelerate ADC development and manufacturing, enabling access to AJICAP technology.

Drug Development | 20/04/2026 | By News Bureau

NHS Speeds Up Clinical Trials, Accelerating Patient Access to New Treatments

The Government-backed reforms and Euro 137 million investment cut trial set-up times, strengthening the UK’s position as a global leader in clinical research and innovation.

Drug Development | 17/04/2026 | By News Bureau

MetaVia Advances Obesity Drug Development with First Patient Dosed in DA-1726 Phase I Trial

MetaVia initiates Part 3 of its phase I trial for DA-1726, evaluating higher-dose strategies to enhance weight loss, metabolic outcomes and tolerability in obesity and cardiometabolic disease treatment.

Drug Development | 13/04/2026 | By News Bureau

Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration

The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.

Drug Development | 08/04/2026 | By News Bureau |  101

EMA Expands PRIME Programme with New Tools to Accelerate Drug Development

EMA introduces three new features to its PRIME scheme, enhancing regulatory support, speeding scientific advice, and improving readiness for marketing authorisation submissions.

Drug Development | 21/03/2026 | By News Bureau

US and European Regulators Set Principles for Responsible AI Use in Drug Development

US and European medicines regulators have jointly issued a set of guiding principles to support the safe, effective and responsible use of artificial intelligence (AI) in drug development, marking a significant step toward regulatory alignment on emerging technologies.

Drug Development | 15/01/2026 | By Darshana |  222

FDA Qualifies First AI Tool to Accelerate Liver Disease Drug Development

The U.S. Food and Drug Administration (FDA) has qualified the world’s first artificial intelligence tool designed to speed up drug development for liver disease.

Drug Development | 10/12/2025 | By Darshana |  1314